OPKO Health Inc (OPK) Q1 2026 Earnings Call Highlights: Navigating Challenges and Seizing ...

This article first appeared on GuruFocus.

Revenue: $124.2 million for Q1 2026, down from $149.9 million in Q1 2025. Diagnostics Revenue: $72.2 million in Q1 2026, including $6.5 million from 4K score test. Pharmaceutical Revenue: $52 million in Q1 2026, up from $47.1 million in Q1 2025. Operating Loss: $51 million for Q1 2026, improved from $67.2 million in Q1 2025. Net Loss: $54.8 million, or $0.07 per share, for Q1 2026, improved from $67.6 million, or $0.10 per share, in Q1 2025. Cash Position: Over $341 million in cash equivalents and restricted cash at the end of Q1 2026. R&D Expenses: $28.8 million in Q1 2026, down from $30.2 million in Q1 2025. Depreciation and Amortization: $18.3 million for pharmaceuticals and $3.9 million for diagnostics in Q1 2026. Pfizer Profit Share: $6.4 million in Q1 2026, a 42% increase from $4.5 million in Q1 2025. BARDA Funding: $4 million in Q1 2026, down from $7 million in Q1 2025.

Warning! GuruFocus has detected 3 Warning Signs with OPK. Is OPK fairly valued? Test your thesis with our free DCF calculator.

Release Date: April 28, 2026

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

OPKO Health Inc (NASDAQ:OPK) made significant progress in its MODEX product development pipeline, with five programs in the clinic across vaccines, oncology, and immunology. The collaboration with Regeneron is advancing well, with potential total value exceeding $1 billion in milestones plus future royalties. The diagnostics business showed improvement, with a 3% increase in accessions per day and margin improvements due to efficiency gains. OPKO Health Inc (NASDAQ:OPK) ended the quarter with a strong cash position of over $341 million, supporting ongoing operations and development plans. The company is on track to achieve breakeven in its diagnostics business by mid-year, reflecting successful restructuring efforts.

Negative Points

First quarter revenue was below previous guidance, primarily due to delays in planned activities under the BARDA contract. The diagnostics business experienced a year-over-year revenue decline due to the oncology divestiture and test mix changes. The pharmaceutical segment reported an operating loss of $30 million, although this was an improvement from the previous year. BARDA funding decreased from $7 million to $4 million year-over-year, impacting revenue from infectious disease programs. The company continues to face challenges in achieving aggressive conversion rates for its InGenla product in the growth hormone market.

Story Continues

Q & A Highlights

Q: Can you comment on the proportion of payer policies updated to reflect the new FDA label for the 4K score test and efforts to engage primary care doctors? A: Adam Logal, CFO, stated that they are working with Medicare to update coverage to reflect the FDA label. While many commercial payers did not require a digital rectal exam, they are waiting for the LCD update before aggressively targeting primary care. This is expected by mid-year.

Q: How should we think about growth expectations for the base business and the contribution of the 4K score? A: Adam Logal, CFO, mentioned that growth is expected in the second half of the year, driven by 4K score and a focused footprint in New York and New Jersey. They anticipate double-digit growth in 4K volumes, contributing to a total business range of $300 million to $312 million.

Q: Can you provide more details on the tetravalent TCE B-cell lymphoma trial and what would be considered good response data? A: Gary Nabel, Chief Innovation Officer, explained that the initial focus is on acceptable toxicity. They are interested in patients who failed CD20 multi-specifics, aiming to salvage therapeutic responses. The trial also explores potential use in autoimmune diseases like lupus.

Q: Any updates on the Merck partnership for the EBV vaccine and data disclosure plans? A: Gary Nabel, Chief Innovation Officer, stated that the Phase I study is progressing well, with no surprises in immunogenicity. They are focusing on EBV-negative patients to down-select adjuvants for Phase II. Data will be available by year-end, with Merck making further decisions.

Q: What are the commercial plans for MDX 2301 for COVID-19 prevention? A: Elias Zerhouni, President, mentioned that they are seeking a partner for development, targeting immune-impaired populations. Gary Nabel added that BARDA might stockpile the product, and they aim to address unmet needs in those who don't respond to vaccines.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

View Comments